Amhr2tm3(cre)Bhr/Amhr2+
Stk11tm1Rdp/Stk11tm1Rdp
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6
|
abnormal seminiferous tubule epithelium morphology |
J:187754
|
|
abnormal seminiferous tubule morphology |
J:187754
|
|
abnormal Sertoli cell morphology |
J:187754
|
|
abnormal spermatogenesis |
J:187754
|
|
abnormal testis morphology |
J:187754
|
|
decreased male germ cell number |
J:187754
|
|
decreased testis weight |
J:187754
|
|
increased Sertoli cell proliferation |
J:187754
|
|
normal
neoplasm |
J:187754
|
|
small testis |
J:187754
|
Stk11tm1.1Arte/Stk11tm1.1Arte
involves: C57BL/6J
|
abnormal cell physiology |
J:208379
|
|
abnormal lipid homeostasis |
J:208379
|
|
abnormal muscle physiology |
J:208379
|
|
normal
homeostasis/metabolism phenotype |
J:208379
|
|
normal
mortality/aging |
J:208379
|
|
normal
reproductive system phenotype |
J:208379
|
Stk11tm1.1Gne/Stk11tm1.1Gne
involves: C57BL/6N
|
abnormal branching involved in lung morphogenesis |
J:195229
|
|
abnormal lung bud morphology |
J:195229
|
|
abnormal lung development |
J:195229
|
|
lethality throughout fetal growth and development, complete penetrance |
J:195229
|
Stk11tm1.1Jish/Stk11+
involves: 129S7/SvEvBrd * C57BL/6J
|
gastric polyps |
J:77213
|
|
increased adenoma incidence |
J:77213
|
|
increased intestinal adenoma incidence |
J:77213
|
Stk11tm1.1Jish/Stk11tm1.1Jish
involves: 129S7/SvEvBrd * C57BL/6J
|
decreased embryo size |
J:77213
|
|
decreased somite size |
J:77213
|
|
embryonic growth retardation |
J:77213
|
|
embryonic lethality during organogenesis, complete penetrance |
J:77213
|
|
incomplete embryo turning |
J:77213
|
Stk11tm1.1Mlfr/Stk11+
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J
|
abnormal intestine morphology |
J:104347
|
|
distended abdomen |
J:104347
|
|
enlarged liver |
J:104347
|
|
enlarged spleen |
J:104347
|
|
enlarged stomach |
J:104347
|
|
gastric polyps |
J:104347
|
|
increased hamartoma incidence |
J:104347
|
|
premature death |
J:104347
|
|
visceromegaly |
J:104347
|
Stk11tm1.1Mlfr/Stk11tm1.1Mlfr
involves: 129S7/SvEvBrd * C57BL/6J
|
embryonic lethality, complete penetrance |
J:104347
|
Stk11tm1.1Rdp/Stk11+
involves: 129S6/SvEvTac * C57BL/6 * SJL
|
no abnormal phenotype detected |
J:78818
|
Stk11tm1.1Rdp/Stk11+
Taglntm1(cre/ERT2)Feil/Tagln+
involves: 129S/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
|
normal
digestive/alimentary phenotype |
J:134476
|
|
gastrointestinal tract polyps |
J:134476
|
|
increased gastrointestinal tumor incidence |
J:134476
|
|
intestinal obstruction |
J:134476
|
|
premature death |
J:134476
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
involves: 129S6/SvEvTac
|
abnormal circulating glucose level |
J:174020
|
|
abnormal gluconeogenesis |
J:174020
|
|
normal
homeostasis/metabolism phenotype |
J:174020
|
|
increased circulating glucose level |
J:174020
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
involves: 129S6/SvEvTac * C57BL/6 * FVB/N
|
normal
neoplasm |
J:124682
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
involves: 129S6/SvEvTac * FVB/N
|
increased endometrial carcinoma incidence |
J:131865
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: 129S6/SvEvTac * C57BL/6J * CBA/J
|
abnormal axon extension |
J:305107
|
|
abnormal axon morphology |
J:305107
|
|
abnormal neuron physiology |
J:305107
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Isl1tm1(cre)Tmj/Isl1+
involves: 129S6/SvEvTac * 129X1/SvJ
|
abnormal cerebral cortex morphology |
J:201695
|
|
normal
behavior/neurological phenotype |
J:201695
|
|
decreased tumor-free survival time |
J:201695
|
|
increased gastrointestinal tumor incidence |
J:201695
|
|
normal
nervous system phenotype |
J:201695
|
|
thin cerebral cortex |
J:201695
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Taglntm1(cre/ERT2)Feil/Tagln+
involves: 129S/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL
|
gastrointestinal tract polyps |
J:134476
|
|
increased gastrointestinal tumor incidence |
J:134476
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Tg(KRT14-cre)1Ipc/0
involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL
|
abnormal hair follicle morphology |
J:131037
|
|
abnormal hair shaft morphology |
J:131037
|
|
corneal opacity |
J:131037
|
|
decreased body size |
J:131037
|
|
delayed hair appearance |
J:131037
|
|
increased squamous cell carcinoma incidence |
J:131037
|
|
reddish skin |
J:131037
|
|
sparse hair |
J:131037
|
|
waved hair |
J:131037
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Tg(Nes-cre)1Kln/0
involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6 * SJL
|
normal
nervous system phenotype |
J:201695
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Tg(Pdx1-cre)89.1Dam/0
involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N * ICR
|
abnormal exocrine pancreas morphology |
J:134078
|
|
abnormal pancreatic acinar cell morphology |
J:134078
|
|
abnormal pancreatic acinus morphology |
J:134078
|
|
abnormal pancreatic islet morphology |
J:134078
|
|
decreased pancreatic alpha cell number |
J:134078
|
|
decreased pancreatic beta cell number |
J:134078
|
|
decreased pancreatic delta cell number |
J:134078
|
|
improved glucose tolerance |
J:134078
|
|
increased circulating glucose level |
J:134078
|
|
increased pancreas apoptosis |
J:134078
|
|
pancreas fibrosis |
J:134078
|
|
pancreas inflammation |
J:134078
|
|
small pancreas |
J:134078
|
|
small pancreatic islets |
J:134078
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Tg(PLAT-cre)116Sdu/0
involves: 129S6/SvEvTac
|
abnormal alveolar process morphology |
J:236402
|
|
abnormal basicranium morphology |
J:236402
|
|
abnormal craniofacial morphology |
J:236402
|
|
abnormal nasal bone morphology |
J:236402
|
|
abnormal neurocranium morphology |
J:236402
|
|
abnormal palatine bone morphology |
J:236402
|
|
abnormal sphenoid bone morphology |
J:236402
|
|
abnormal suckling behavior |
J:236402
|
|
cleft secondary palate |
J:236402
|
|
decreased body height |
J:236402
|
|
decreased bone mineral density |
J:236402
|
|
decreased bone ossification |
J:236402
|
|
large anterior fontanelle |
J:236402
|
|
micrognathia |
J:236402
|
|
neonatal lethality, complete penetrance |
J:236402
|
|
short mandible |
J:236402
|
|
short snout |
J:236402
|
|
small basisphenoid bone |
J:236402
|
|
small cranium |
J:236402
|
|
small frontal bone |
J:236402
|
|
small maxilla |
J:236402
|
|
small parietal bone |
J:236402
|
|
small premaxilla |
J:236402
|
|
small presphenoid bone |
J:236402
|
|
small temporal bone squamous part |
J:236402
|
|
small vomer bone |
J:236402
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Tg(Sprr2f-cre)1Dcas/0
involves: 129S6/SvEvTac * FVB/N
|
abnormal myometrium morphology |
J:158190
|
|
abnormal urinary bladder morphology |
J:158190
|
|
abnormal uterus size |
J:158190
|
|
hydronephrosis |
J:158190
|
|
increased endometrial carcinoma incidence |
J:158190
|
|
increased metastatic potential |
J:158190
|
|
increased uterus weight |
J:158190
|
|
peritoneal inflammation |
J:158190
|
|
premature death |
J:158190
|
|
sepsis |
J:158190
|
|
urinary bladder obstruction |
J:158190
|
Stk11tm1.1Rdp/Stk11tm1.2Rdp
involves: 129S6/SvEvTac * C57BL/6 * FVB/N
|
normal
neoplasm |
J:124682
|
Stk11tm1.1Sjm/Stk11tm1.1Sjm
Ndor1Tg(UBC-cre/ERT2)1Ejb/0
involves: 129S/SvEv * C57BL/6 * SJL
|
abnormal bone marrow cell physiology |
J:165090
|
Stk11tm1.1Sjm/Stk11tm1.1Sjm
Tg(Mx1-cre)1Cgn/0
involves: C57BL/6 * CBA * SJL
|
abnormal bone marrow cell morphology/development |
J:165090
|
|
abnormal bone marrow cell physiology |
J:165090
|
|
abnormal mitotic spindle morphology |
J:165090
|
|
aneuploidy |
J:165090
|
|
normal
cellular phenotype |
J:165090
|
|
decreased bone marrow cell number |
J:165090
|
|
decreased erythrocyte cell number |
J:165090
|
|
decreased hematopoietic stem cell number |
J:165090
|
|
decreased leukocyte cell number |
J:165090
|
|
increased hematopoietic stem cell number |
J:165090
|
|
increased mitochondrial fission |
J:165090
|
|
pancytopenia |
J:165090
|
|
thrombocytopenia |
J:165090
|
|
thymus hypoplasia |
J:165090
|
Stk11tm1.2Rdp/Stk11+
involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL
|
gastrointestinal tract polyps |
J:134476
|
|
increased gastrointestinal tumor incidence |
J:134476
|
|
premature death |
J:134476
|
Stk11tm1.2Rdp/Stk11+
involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL
|
abnormal digestive system physiology |
J:78818
|
|
colon polyps |
J:78818
|
|
gastric polyps |
J:78818
|
|
gastrointestinal tract polyps |
J:78818
|
|
increased hamartoma incidence |
J:78818
|
|
increased incidence of tumors by chemical induction |
J:131037
|
|
increased tumor incidence |
J:78818,
J:131037
|
|
intestinal obstruction |
J:78818
|
|
premature death |
J:131037
|
Stk11tm1.2Rdp/Stk11+
involves: 129S6/SvEvTac * FVB/N
|
increased endometrial carcinoma incidence |
J:131865
|
|
intestine polyps |
J:131865
|
Stk11tm1.2Rdp/Stk11tm1.2Rdp
involves: 129S6/SvEvTac
|
abnormal cell differentiation |
J:141132
|
Stk11tm1.2Rdp/Stk11tm1.2Rdp
involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL
|
abnormal cell cycle |
J:78818
|
|
abnormal cell physiology |
J:78818
|
|
abnormal placenta development |
J:78818
|
|
abnormal vasculogenesis |
J:78818
|
|
embryonic lethality, complete penetrance |
J:78818
|
Stk11tm1Keis/Stk11tm1Keis
Not Specified
|
normal
growth/size/body region phenotype |
J:98513
|
|
normal
homeostasis/metabolism phenotype |
J:98513
|
|
male infertility |
J:98513
|
|
perinatal lethality, incomplete penetrance |
J:98513
|
Stk11tm1Keis/Stk11tm1Keis
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd
|
increased circulating interleukin-10 level |
J:191723
|
Stk11tm1Keis/Stk11tm1Keis
Tg(Ckmm-cre)5Khn/0
involves: FVB
|
decreased muscle cell glucose uptake |
J:98513
|
|
normal
growth/size/body region phenotype |
J:98513
|
|
male infertility |
J:98513
|
Stk11tm1Keis/Stk11tm1Keis
Tg(Cyp1a1-cre/ERT)1Dwi/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA
|
gastric polyps |
J:169565
|
|
normal
renal/urinary system phenotype |
J:169565
|
Stk11tm1Keis/Stk11tm1Keis
Tg(Pomc1-cre)1Gsb/0
involves: FVB/N
|
abnormal gluconeogenesis |
J:170130
|
|
abnormal glycogen homeostasis |
J:170130
|
|
decreased fluid intake |
J:170130
|
|
normal
endocrine/exocrine gland phenotype |
J:170130
|
|
normal
homeostasis/metabolism phenotype |
J:170130
|
|
impaired glucose tolerance |
J:170130
|
|
insulin resistance |
J:170130
|
|
normal
nervous system phenotype |
J:170130
|
Stk11tm1Mmt/Stk11+
involves: 129X1/SvJ
|
gastric polyps |
J:76202
|
|
increased hamartoma incidence |
J:76202,
J:107275
|
|
increased hepatocellular carcinoma incidence |
J:76202
|
|
increased tumor incidence |
J:76202
|
|
premature death |
J:76202
|
Stk11tm1Mmt/Stk11tm1Mmt
involves: 129X1/SvJ
|
embryonic lethality, complete penetrance |
J:76202
|
Stk11tm1Tpm/Stk11+
involves: 129S7/SvEvBrd * C57BL/6 * CD-1
|
decreased tumor incidence |
J:93361
|
|
gastric polyps |
J:93361
|
|
intestine polyps |
J:93361
|
Stk11tm1Tpm/Stk11+
Not Specified
|
distended abdomen |
J:79074
|
|
duodenum polyps |
J:79074
|
|
gastric polyps |
J:79074
|
|
increased endometrial carcinoma incidence |
J:79074
|
|
increased hemangioma incidence |
J:79074
|
|
increased hepatocellular carcinoma incidence |
J:79074
|
|
increased liver adenoma incidence |
J:79074
|
|
intestinal obstruction |
J:79074
|
|
intestine polyps |
J:79074
|
|
premature death |
J:79074
|
Stk11tm1Tpm/Stk11tm1Tpm
Not Specified
|
abnormal dorsal aorta morphology |
J:70892
|
|
abnormal embryo turning |
J:70892
|
|
abnormal head mesenchyme morphology |
J:70892
|
|
abnormal neural fold formation |
J:70892
|
|
abnormal neural tube closure |
J:70892
|
|
abnormal notochord morphology |
J:70892
|
|
abnormal placental labyrinth vasculature morphology |
J:70892
|
|
abnormal somite development |
J:70892
|
|
abnormal spongiotrophoblast layer morphology |
J:70892
|
|
abnormal vascular smooth muscle morphology |
J:70892
|
|
abnormal visceral yolk sac morphology |
J:70892
|
|
abnormal vitelline vasculature morphology |
J:70892
|
|
absent first pharyngeal arch |
J:70892
|
|
absent vitelline blood vessels |
J:70892
|
|
delayed chorioallantoic fusion |
J:70892
|
|
embryonic lethality during organogenesis, complete penetrance |
J:70892
|
|
first pharyngeal arch hypoplasia |
J:70892
|
|
placenta hemorrhage |
J:70892
|
|
small placenta |
J:70892
|
Stk11tm2.1Arte/Stk11tm2.1Arte
involves: C57BL/6J
|
no abnormal phenotype detected |
J:208379
|
Excel File
Analysis Tools